Corporate boards should take note that the situation at Progenics Pharmaceuticals has resulted in a proxy advisory firm validating a call for “shareholder board oversight.” Serving on a board that has been sighted for oversight by its investors could have an effect on future board appointments.
A look back at the first half of 2018 shows that shareholder activism continues at record pace, passive asset managers are growing larger and have found their ESG-centric voice.
Chief Executive Group exists to improve the performance of U.S. CEOs, senior executives and public-company directors, helping you grow your companies, build your communities and strengthen society. Learn more at chiefexecutivegroup.com.